Understanding how prostate cancer develops resistance to treatment at the single cell level
Studying the evolution of drug resistance in prostate cancer at the single cell level
This study is looking at how prostate cancer cells change and become resistant to treatments, so we can find better ways to help patients like you respond to therapy and improve outcomes.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Columbia University Health Sciences NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-11072772 on NIH RePORTER |
What this research studies
This research investigates the mechanisms behind drug resistance in prostate cancer by examining individual cancer cells. It aims to identify how these cells adapt and evolve in response to treatments, which can lead to treatment failure and disease progression. By utilizing advanced technologies and computational methods, the study will create detailed molecular interaction networks that reveal how cancer cells communicate and interact with their environment. This approach seeks to uncover universal targets for more effective therapies in heterogeneous tumors.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with advanced prostate cancer who have not responded well to existing therapies.
Not a fit: Patients with early-stage prostate cancer or those who have not yet undergone treatment may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to the development of more effective treatments for prostate cancer that overcome drug resistance.
How similar studies have performed: Previous research has shown promise in understanding drug resistance in cancer using similar methodologies, indicating potential for success in this approach.
Where this research is happening
New York, United States
- Columbia University Health Sciences — New York, United States (Active)
Researchers
- Principal investigator: Califano, Andrea — Columbia University Health Sciences
- Study coordinator: Califano, Andrea
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.